Examkin

Question

Difficulty: MediumHematology and Oncology

A 52-year-old woman with a history of breast cancer is evaluated in the emergency department for a fever that began earlier today. She received her last cycle of chemotherapy consisting of doxorubicin and cyclophosphamide 8 days ago. Her temperature is 38.6∘C38.6^\circ\text{C} (101.5∘F101.5^\circ\text{F}), blood pressure is 112/72 mmHg112/72 \text{ mmHg}, and heart rate is 98 /min98 \text{ /min}. Physical examination reveals a totally implanted central venous port in the right upper chest with no surrounding erythema, and no other clear source of infection. A complete blood count reveals a hemoglobin of 10.2 g/dL10.2 \text{ g/dL}, platelet count of 115,000/mm3115,000/\text{mm}^3, and a white blood cell count of 800/mm3800/\text{mm}^3 with 30%30\% neutrophils. Arrange the following management steps in the most appropriate chronological sequence for this patient.

  1. 1Obtain blood cultures from the central venous port and a peripheral vein
  2. 2Administer empiric broad-spectrum intravenous antibiotics (e.g., cefepime)
  3. 3Monitor clinical response and review initial culture growth after 48 to 72 hours
  4. 4De-escalate or tailor the antimicrobial regimen based on susceptibility data

Answer

The correct sequence for managing febrile neutropenia is to first obtain blood cultures, immediately follow with empiric broad-spectrum antibiotics, monitor for 48-72 hours, and finally tailor the regimen based on culture results.
The standard of care for febrile neutropenia follows a strict chronological sequence to maximize patient safety and diagnostic yield. First, blood cultures must be drawn from all existing central lines and a peripheral site to ensure accurate pathogen identification before any antibiotics are introduced. Immediately following the culture draw, empiric broad-spectrum intravenous antibiotics with antipseudomonal activity (e.g., cefepime, meropenem, or piperacillin-tazobactam) must be administered. Delaying this step can lead to overwhelming sepsis and death. The patient is then monitored for 48 to 72 hours to assess clinical response while the laboratory incubates the cultures. Finally, once susceptibility data is available or clinical stability is achieved, the antibiotic regimen is de-escalated or tailored to provide targeted therapy, minimizing toxicity and the development of resistance.

Step-by-Step Solution

1
Recognize the diagnosis of febrile neutropenia.
The patient has a fever (38.6∘C38.6^\circ\text{C}) and an absolute neutrophil count of 240/mm3240/\text{mm}^3 (800×0.30800 \times 0.30), confirming a high-risk oncologic emergency.
Febrile neutropenia requires a rapid, protocolized approach to prevent life-threatening sepsis.
2
Determine the first immediate action.
Blood cultures (both central and peripheral) and other appropriate workups must be drawn.
Securing cultures before introducing any antimicrobial agents is critical to identifying the organism and avoiding false-negative results.
3
Determine the next immediate action.
Initiation of empiric antipseudomonal antibiotics (e.g., cefepime).
Because patients lack neutrophils to fight infection, empiric coverage for high-risk organisms like Pseudomonas aeruginosa must begin within 1 hour of presentation.
4
Establish the subsequent follow-up plan.
Monitor the patient for 48-72 hours while waiting for culture data.
It takes time for cultures to grow and for the patient to demonstrate a clinical response to empiric therapy.
5
Determine the final management step.
Modify the antibiotic regimen based on culture and susceptibility results.
Targeted therapy prevents antibiotic resistance and minimizes adverse effects.

Key Concept

The management of febrile neutropenia requires obtaining microbiological cultures first, immediately followed by the administration of empiric broad-spectrum antipseudomonal antibiotics, with subsequent de-escalation based on culture data.
Rate this question

Topics

Hematology and Oncology

More questions from this topic